BioCentury | May 4, 2018
Clinical News

Daiichi reports Phase I/II data for DMD candidate

...Daiichi Sankyo Co. Ltd. (Tokyo:4568) said once-weekly subcutaneous DS-5141 missed the primary endpoint of improving dystrophin...
...see BioCentury, May 2, 2017) . Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: DS-5141 (DS-5141b...
...mRNA in muscle tissue at week 12 Status: Phase I/II data Milestone: NA Jaime De Leon DS-5141, DS-5141b Daiichi...
BioCentury | May 3, 2017
Clinical News

DMD candidate DS-5141 receives Sakigake designation in Japan

...to DS-5141 (DS-5141b) from Daiichi Sankyo Co. Ltd. (Tokyo:4568) to treat Duchenne muscular dystrophy (DMD). DS-5141...
...Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: DS-5141 (DS-5141b) Business: Musculoskeletal Alicia Parker DS-5141b Daiichi Sankyo Co. Ltd. Dystrophin DS-5141...
BioCentury | Apr 28, 2017
Politics, Policy & Law

Access and innovation in Japan

...Sanofi (Euronext:SAN; NYSE:SNY) Olipudase Alfa Acid sphingomyelinase deficiency Ph II/III Daiichi Sankyo Co. Ltd. (Tokyo:4568) DS-5141b...
BioCentury | Mar 7, 2016
Clinical News

DS-5141b: Phase I/II started

...evaluate subcutaneous DS-5141b in about 6 patients. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: DS-5141b...
Items per page:
1 - 4 of 4